Gillian McGovern, Editor

The FDA approves retifanlimab for advanced anal cancer, offering new hope with improved survival rates and treatment options for patients.

The approved injection contains dihydroergotamine (DHE), which is the same medication used in hospitals, in a ready-to-use device.

The announcement came shortly before updated results from the SURMOUNT-5 clinical trial, which found Zepbound had superior weight-loss effects over Wegovy.

Effectively communicating research findings to patients, health care professionals, and policy payers is necessary for engagement.

Artificial intelligence (AI) can transform rare disease research by leveraging patient data, enhancing evidence generation, and improving communication between patients and health care professionals.

Maternal cardiometabolic issues during pregnancy significantly elevate children's blood pressure, highlighting the need for preventive health measures.

During a panel discussion, 3 experts highlighted ways health care professionals and researchers can help provide patient-centered care.

In approximately 84% of cases, the mask was able to detect if patients had chronic kidney disease (CKD).

The new at-home test aims to increase comfort and screening timeliness through a more accessible method.

These findings demonstrate an association that is independent of the disease’s genetic predisposition.

With the FDA approval, avutometinib/defactinib is now the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).

These results build off prior studies which demonstrated effectiveness of Bergen 4-day treatment (B4DT) in patients with panic disorders.

Necrotizing enterocolitis (NEC) is a life-threatening illness that is characterized by the inflammation of the intestinal lining, which can lead to intestinal perforation.

The coronary artery disease (CAD) predictive model help health care professionals tailor personalized treatment methods for patients.

This screening method can help empower patients to better manage their health and seek additional care.

About 62.9% of patients with metabolic dysfunction–associated steatohepatitis (MASH) receiving semaglutide experienced resolution of steatohepatitis without worsening of fibrosis.

Jennifer Guthrie, RPh, district leader at CVS pharmacy describes the different medications to treat allergy symptoms and highlight how CVS stands out when addressing patients’ needs.

Currently, the treatment is undergoing evaluation in a 3-part clinical trial to determine its safety, efficacy, and pharmacokinetics in patients with recurrent advanced/metastatic cancers.

In chronic hepatitis B (CHB) mouse models, the ferritin nanoparticle-preS1 (ferritin-NP-preS1) with small interfering RNA (siRNA) showed 100% and sustained serum HBsAg over an approximate 11-month period.

Reductions of approximately 32% were observed during the study.

Paula E. Voinescu, PhD, MD, emphasized the need for additional research in this area, noting it is both “surprising and upsetting.”

The condition, which is common in patients with chronic kidney disease (CKD), is characterized by skin lesions and currently has no curative treatment.

In the treatment of metabolic dysfunction-associated steatohepatitis (MASH), engineered extracellular vesicles helped mitigate disease progression and did not compromise bone density.

In clinical trials, the dihydroergotamine (DHE) nasal powder had favorable safety profiles and rapid pain relief in patients with migraine with or without aura.

At Baptist Health South Florida, pharmacists are embedded in all areas of cardiovascular care, an expert said.

Nipocalimab the first and only FcRn blocker approved in anti-acetylcholine receptor– or anti-muscle-specific kinase adults and children with generalized myasthenia gravis.

A 15-mg dose with a corticosteroid taper regimen was superior to placebo in sustained remission from week 12 to 52.

Although participants noted symptom relief, there was not a dietary modification uniquely perceived as beneficial.

The treatment received indications as a monotherapy and in combination regimen with carboplatin or cisplatin and gemcitabine.

Because mothers are already at risk of depression postpartum, health care professionals must properly counsel mothers on hormonal contraceptives.